Company / Shareholders' Equity
ENDRA Life Sciences Inc. Shareholders' Equity History
FY2017-FY2020 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$7.2M
FY2020
5-year range
$5.3M / $7.2M
FY2017-FY2020
Trend
+14.7%
vs FY2019
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $5M to $7M over the past 2 years.
Based on SEC 10-K filings.
$7M in FY2020 with a 3-year CAGR of +10.8%.
Improved from $5M to $7M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +10.8%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +10.8%, indicating consistent growth.
- In FY2020, shareholders' equity increased 14.7% year-over-year.
Company context
Key Data Points
- Altman Z-Score -7.14 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2020 | $7.2M | +14.7% |
| FY2019 | $6.2M | +18.4% |
| FY2018 | $5.3M | +0.0% |
| FY2017 | $5.3M | - |
As of FY2020 · SEC 10-K · Updated Jun 28, 2026